Pulmonary Vascular Disease
Among patients with idiopathic interstitial pneumonia associated with pulmonary hypertension, treatment with riociguat was linked to an increase in adverse events with no significant evidence of benefit, according to the RISE-IIP trial.
In fact, the international, multicenter, double-blind, randomized, placebo-controlled phase 2b trial was terminated early due to a higher incidence of deaths, serious adverse events and adverse event-related drug discontinuations in patients treated with riociguat (Adempas, Bayer) vs. placebo, researchers wrote in The Lancet Respiratory Medicine.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.